Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_assertion type Assertion NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_head.
- NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_assertion description "[Janus kinase 2 (JAK2) V617F mutation testing has revolutionized the classification of myeloproliferative disorders, for which several tests have been introduced for qualitative and quantitative diagnostics including the MutaScreen and MutaQuant kits by IPSOGEN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_provenance.
- NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_assertion evidence source_evidence_literature NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_provenance.
- NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_assertion SIO_000772 21933004 NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_provenance.
- NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_assertion wasDerivedFrom befree-2016 NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_provenance.
- NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_assertion wasGeneratedBy ECO_0000203 NP925066.RAfQufK3zkTGqI8CMN_HyCd-gFAu2LVBG32vas-wlUjnI130_provenance.